Danbury and Norwalk hospitals have opened two new clinical trials for people with advanced-stage cancer that have a KRAS G12C mutation. The Danbury Hospital clinical trial is for patients with advanced metastatic non-small cell lung cancer. The Norwalk Hospital clinical trial is for patients with certain types of solid tumors, such as advanced colorectal cancer.  They are the only sites in Fairfield County offering these clinical trials.  Officials say this can provide a new treatment for patients who otherwise might be out of options because of the advanced-stage of their cancer.  Danbury and Norwalk hospitals are currently enrolling patients into the clinical trials through the Oncology Research Department.  The clinical trials are studying a new drug called AMG 510. Early evidence shows that AMG 510 blocks KRAS G12C, a variant of KRAS. KRAS is a key enzyme in the growth of many cancers. A patient will know if their cancer has a KRAS G12C mutation after a tumor specimen undergoes genomic profiling, which the patient’s oncologist will order. Danbury and Norwalk hospitals encourage any cancer patient with a KRAS G12C mutation to contact the hospitals about the clinical trials.